11Mar

HPRA Drug Safety Newsletter 66

This is a podcast based on the 66th edition of the HPRA Drug Safety Newsletter. Topics covered in this edition include:

Eligard (leuprorelin acetate depot injection)

Beta interferons

Mycophenolate mofetil (CellCept) and Mycophenolic acid (Myfortic)

Tecfidera (dimethyl fumarate)

Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The HPRA is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 
00:0000:00

11Mar

HPRA Drug Safety Newsletter 65

This is a podcast based on the 65th edition of the HPRA Drug Safety Newsletter. Topics covered in this edition include:

Valproate-containing Medicines: 

Recommendation to further restrict the use of valproate in

women and girls

Ivabradine (Procoralan):

New contraindication and recommendations to minimise the risk of cardiovascular events and severe bradycardia

Agomelatine (Valdoxan):

Reminder of the importance of liver function monitoring to reduce the risk of serious hepatic adverse reactions.

Testosterone Medicines:: review does not confirm increased risk of cardiovascular events - recommends medicines can continue to be prescribed for their authorised indications

Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The HPRA is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 
00:0000:00

11Mar

HPRA Drug Safety Newsletter 64

This is a podcast based on the 64th edition of the HPRA Drug Safety Newsletter. Topics covered in this edition include:

Oral Anticoagulants: 

Update on National Monitoring Experience


Chlorhexidine cutaneous solutions: 

Chemical injury including burns when used in skin disinfection in premature infants


Adverse Reaction Reporting  Reminder


Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The HPRA is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 
00:0000:00

11Mar

HPRA Drug Safety Newsletter 63

This is a podcast based on the 63rd edition of the HPRA Drug Safety Newsletter. Topics covered in this edition include:

Transdermal fentanyl:

Reminder about the potential for life-threatening harm from accidental exposure to transdermal fentanyl

Denosumab (Prolia):

Updated information to minimise the risk of osteonecrosis of the jaw and hypocalcaemia

Ferumoxytol (Rienso):

New important advice to mitigate the risk of serious hypersensitivity reactions.

Beta interferons: Risk of thrombotic microangiopathy and nephrotic syndrome

Adverse Reaction Reporting    during 2013

Direct Healthcare Professional Communications published on HPRA website since the last Drug Safety Newsletter


A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The HPRA is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 
00:0000:00

24Sep

IMB Drug Safety Newsletter 60

This is a podcast based on the 60th edition of the IMB Drug Safety Newsletter. Topics covered in this edition include:

  • Strontium ranelate (Protelos) – New restricted indication and monitoring recommendations due to concerns
  • regarding cardiovascular safety
  • Hydroxyethylstarch (HES) Infusion Solutions – EU review confirms they are not to be used in patients with sepsis or
  • burn injuries or in critically ill patients
  • Cetuximab (Erbitux) – Update on revised recommendations for use and risk of infusion-related reactions
  • Direct Healthcare Professional Communications published on the IMB website since the last Drug Safety Newsletter
A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The IMB is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 
00:0000:00

24Sep

IMB Drug Safety Newsletter No. 59

This is a podcast based on the 59th edition of the IMB Drug Safety Newsletter. Topics covered in this edition include:

  • Combined Hormonal Contraceptives – Update on Risk of Venous Thromboembolism
  • Electronic Distribution of the IMB Drug Safety Newsletter (DSN)
  • Direct Healthcare Professional Communications published on the IMB website since the last Drug Safety Newsletter
A (free) CPD accredited presentation based on the Drug Safety Newsletter is also available (visit www.iacme.ie for more details).  While every effort has been made to ensure the accuracy of this podcast, iaCME Ltd are not responsible for any errors or ommissions.  The actual Newsletter is available here. (The IMB is in agreement with the use of its DSN for the purpose of CPD and has contributed to review of the individual modules prior to release.)

Click on the play button to start listening. 

15Apr

INTERNAL CME

The Value of Reflection and its role in CPD or “Internal CME”

CPD is not simply about ticking boxes and answering MCQs to demonstrate that our knowledge or skills have been enhanced in some way. CPD activities should also influence our behaviour if they are to have a meaningful impact on professional practice.  This requires a certain “slowing down” of the learning process so that we have time to reflect on what we have learned and how it relates to our practice and patient care. In effect it helps to “internalise” the learnings and make them relevant to our individual development.

In the medical profession, there is a category of CPD called “internal CME” which relates to internal practice evaluation and development as opposed to “external CME” which relates to meetings/presentations hosted by a third party.  External CME usually includes some form of assessment, such as MCQs, to demonstrate that learning has taken place. 

iaCME’s presentation of the IMB Drug Safety Newsletters as online CPD modules presents an ideal opportunity to combine both types of CPD.  The interactive presentations can help keep up to date with new safety information and learners who successfully complete the embedded quizzes gain accredited CPD points.  Additionally, however, by reflecting on the IMB’s Advice issued in each edition, the modules also serve as a valuable stimulus to evaluate practice and to enhance the quality and safety of patient care.

Reflection can be a difficult concept to grasp for those new to the idea.  In practice, we all probably reflect informally on new information to a greater and lesser degree but a structured approach will optimise the benefits of reflection.  A useful resource to support practice evaluation, therefore, are the Reflection Tools provided within iaCME’s DSN Modules.   Using the Reflection Tools might be expected to stimulate such things as: chart reviews, clinical case discussions, patient surveys, Primary Care Team (PCT) meetings, peer-review groups, practice-based meetings, quality improvement projects and significant event analysis. These activities are included in the ICGP’s list of activities which fall under the “internal CME” category.  The time spent on these practice-based activities should be recorded separately from the on-line activity and, for the medical profession, this should be categorised as “internal CME”. 

iaCME modules include on-line discussion forums which are restricted to healthcare professionals in accordance with iaCME’s Privacy Policy.  They can be used to discuss general topics or even (anonymised) clinical issues and approaches to patient care with other healthcare professionals.  There are not many opportunities for inter-professional discussions and these forums provide an ideal platform for such engagement in a restricted environment.  A description of the discussion with details of time spent, contributors and topics and any conclusions/plans should be recorded.  Print-outs or electronic copies of the discussions can be useful as further evidence of your participation for audit purposes.

Documentation can be retained in hard copy in your practice or can be stored electronically on an eportfolio.  iaCME’s learning environment also offers storage space for personal files which can be used for this purpose also.

Note:  The iaCME module on “The Prescribing Cascade” (short module including a recording of an inter-professional discussion on the topic of prescribing additional meds to cover unrecognised reactions to a previously prescribed medicine) is also a suitable module for Internal CME.

 

 

22Feb

WHITHER PHARMACY CPD IN IRELAND?

Jack Shanahan’s always thought-provoking “In the Frontline” series in the IPU this month looked at Pharmacy CPD and the current seeming hiatus in rolling out a framework for the future system. Jack’s worry is that the new Institute of Pharmacy will be caught in a conflict of interest in setting standards for provision of CPD while also controlling the commissioning of training. The fear could be that the development of standards might work to exclude competition. We at iaCME would be much more optimistic about the future – the new CPD system recognises the benefits of all types of learning much of which will be self-directed based on personal needs. As regards accreditation, the Institute will be able to draw on international experience and will surely arrive at a robust and transparent process for accreditation. iaCME have liaised with and worked through many accreditation mechanisms in Ireland, UK, Europe and the U.S. and appreciate the need for quality assurance. As for possible unfair exclusion of providers, remember, the Institute has been set up by the PSI and, while it will operate independently, must be subject to scrutiny by the PSI in the interests of the best CPD for Pharmacists and ultimately the best interests of patients.

We do have a couple of concerns regarding the future system. The first would be that, while the Institute should outline minimum specifications for the portfolio that must be maintained, Pharmacists should not be tied to a portfolio hosted by the Institute. That is an area where monopoly could arise and where the value of Pharmacists’ knowledge of their own individual practical learning requirements could be significantly impaired.

The other area of concern is a more fundamental conflict of interest scenario in the provision of CPD. The current interim guidelines allow sponsors to actually deliver education. Best international practice today includes significant arms-length controls to ensure no sponsor bias.

iaCME are an independent provider of accredited CPD for Healthcare professionals. Details of our latest modules are available by clicking HERE.